Thursday, May 07, 2026 11:38:00 AM
Zadie, this is where $nwbo now being a part of the Parker Institute for Cancer Immunotherapy will pay dividends, in fact only today I posted their new announcement on X.....
"We’re excited to share that Aimee Johnson has joined PICI as Chief Marketing Officer.
A seasoned marketing leader with more than 30 years of experience, Aimee will lead brand, marketing, and digital strategy in support of PICI’s impact and growth. Her leadership will strengthen our ability to amplify our mission and accelerate the development and delivery of breakthrough cancer therapies"
Please join us in welcoming Aimee to PICI!
Read more here: https://parkerici.org/the-latest/parker-institute-for-cancer-immunotherapy-announces-appointment-of-aimee-johnson-as-chief-marketing-officer/
"Her leadership will strengthen our ability to amplify our mission and accelerate the development and delivery of breakthrough cancer therapies"
"We’re excited to share that Aimee Johnson has joined PICI as Chief Marketing Officer.
A seasoned marketing leader with more than 30 years of experience, Aimee will lead brand, marketing, and digital strategy in support of PICI’s impact and growth. Her leadership will strengthen our ability to amplify our mission and accelerate the development and delivery of breakthrough cancer therapies"
Please join us in welcoming Aimee to PICI!
Read more here: https://parkerici.org/the-latest/parker-institute-for-cancer-immunotherapy-announces-appointment-of-aimee-johnson-as-chief-marketing-officer/
"Her leadership will strengthen our ability to amplify our mission and accelerate the development and delivery of breakthrough cancer therapies"
#dcvax $nwbo #gbm
— Peter Davis (@peter_brit) May 7, 2026
"Her leadership will strengthen our ability to amplify our mission and accelerate the development and delivery of breakthrough cancer therapies" https://t.co/c5rUh7T5yb
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
